Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances) · 82.6M shares · +13%/yr ↑ dilution · EDGAR filings ↗
Reference price $9.24 · est. market cap ~$763M — last insider sale, 2026-06-01 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — oncolytic-immunotherapy clinical, well-funded.
Strengths
- Liquidity — current ratio 8.0 (73rd)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +13%/yr over 3y (dilution, book value/share -30%)
- Strong balance sheetStrong balance sheet — $484M cash & investments
- Notable holderHeld by 5 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, FMR LLC +2 more (as of 2026-03-31)
- Insider sellingInsider selling — 8 open-market sale(s) by 6 insider(s) (cluster of 6 insiders, ~$637,092, last 6mo) Form 4 ↗
Quarterly revenue
Last 3 quarters · from SEC filings.
Key metrics
Return on equity
-59.5%
Return on assets
-44.9%
ROIC
-44.7%
Debt / equity
0.1×
Current ratio
8.0×
EBITDA
-$258M
Tangible book value
$416M
Cash & investments
$484M
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-01 | Sarchi Christopher | Sell | 12K | $9.24 |
| 2026-05-18 | Sarchi Christopher | Sell | 8.6K | $5.08 |
| 2026-05-18 | Astley-Sparke Philip | Sell | 18K | $5.08 |
| 2026-05-18 | Patel Sushil | Sell | 37K | $5.08 |
| 2026-05-18 | Xynos Konstantinos | Sell | 14K | $5.08 |
| 2026-05-18 | Schwendenman Andrew | Sell | 7.9K | $5.08 |
| 2026-05-18 | Hill Emily Luisa | Sell | 7.8K | $5.08 |
| 2026-04-02 | Sarchi Christopher | Sell | 6.5K | $8.01 |
| 2026-04-01 | Sarchi Christopher | Grant | 50K | — |
| 2026-04-01 | Astley-Sparke Philip | Grant | 50K | — |
| 2026-04-01 | Xynos Konstantinos | Grant | 50K | — |
| 2026-04-01 | Schwendenman Andrew | Grant | 37K | — |
| 2026-04-01 | Patel Sushil | Grant | 251K | — |
| 2026-04-01 | Hill Emily Luisa | Grant | 50K | — |
| 2026-02-18 | Astley-Sparke Philip | Gift | 25K | — |
| 2025-12-19 | Sarchi Christopher | Grant | 35K | — |
| 2025-12-19 | Patel Sushil | Grant | 200K | — |
| 2025-12-19 | Xynos Konstantinos | Grant | 60K | — |
| 2025-12-19 | Hill Emily Luisa | Grant | 60K | — |
| 2025-12-19 | Schwendenman Andrew | Grant | 10K | — |
| 2025-12-09 | Dhingra Kapil | Option exercise | 3.2K | $1.75 |
| 2025-12-09 | Dhingra Kapil | Sell | 3.2K | $10.40 |
| 2025-12-02 | Patel Sushil | Sell | 10K | $11.13 |
| 2025-11-17 | Sarchi Christopher | Sell | 5.2K | $9.10 |
| 2025-11-17 | Xynos Konstantinos | Sell | 7.2K | $9.10 |
| 2025-08-15 | Hill Emily Luisa | Sell | 9.2K | $5.37 |
| 2025-05-20 | Astley-Sparke Philip | Sell | 32K | $8.06 |
| 2025-05-20 | Xynos Konstantinos | Sell | 8.0K | $8.06 |
| 2025-05-20 | Schwendenman Andrew | Sell | 3.3K | $8.05 |
| 2025-05-20 | Patel Sushil | Sell | 25K | $8.06 |
| 2025-05-20 | Hill Emily Luisa | Sell | 2.5K | $8.05 |
| 2025-05-20 | Sarchi Christopher | Sell | 3.7K | $8.05 |
| 2025-04-01 | Patel Sushil | Grant | 167K | — |
| 2025-04-01 | Xynos Konstantinos | Grant | 45K | — |
| 2025-04-01 | Hill Emily Luisa | Grant | 45K | — |
| 2025-04-01 | Sarchi Christopher | Grant | 45K | — |
| 2025-04-01 | Schwendenman Andrew | Grant | 33K | — |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-26 | Reg FDExhibits | filing ↗ |
| 2026-05-29 | Reg FDExhibits | filing ↗ |
| 2026-04-13 | Reg FDOtherExhibits | filing ↗ |
| 2026-02-03 | Material agreementResultsDebt obligationExhibits | filing ↗ |
| 2026-01-12 | Reg FDExhibits | filing ↗ |
| 2025-11-06 | ResultsExhibits | filing ↗ |
| 2025-10-20 | OtherExhibits | filing ↗ |
| 2025-09-18 | Reg FDOtherExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-26 | 2026-06-26 | 0001104659-26-078009 ↗ |
| 8-K | 2026-05-29 | 2026-05-29 | 0001104659-26-068002 ↗ |
| 8-K | 2026-04-13 | 2026-04-10 | 0001104659-26-042141 ↗ |
| 8-K | 2026-02-03 | 2026-02-03 | 0001104659-26-009510 ↗ |
| 10-Q | 2026-02-03 | 2025-12-31 | 0001628280-26-004805 ↗ |
| 8-K | 2026-01-12 | 2026-01-12 | 0001104659-26-002721 ↗ |
| 8-K | 2025-11-06 | 2025-11-06 | 0001104659-25-107438 ↗ |
| 10-Q | 2025-11-06 | 2025-09-30 | 0001628280-25-049884 ↗ |
| 8-K | 2025-10-20 | 2025-10-20 | 0001104659-25-100605 ↗ |
| 8-K | 2025-09-18 | 2025-09-16 | 0001104659-25-091066 ↗ |
| 8-K | 2025-09-04 | 2025-09-02 | 0001104659-25-087464 ↗ |
| 10-Q | 2025-08-07 | 2025-06-30 | 0001737953-25-000013 ↗ |